Literature DB >> 17375268

[AnaConDa as last resort treatment. Case report of a chronic obstructive pulmonary disease].

E A Nickel1, I Benken, U Bartels, W G Voelckel, M Quintel.   

Abstract

Treatment of patients suffering from decompensated chronic pulmonary disease (COPD) not responding to pharmacological therapy is still a major challenge in intensive care medicine. Administration of volatile anaesthetics may be a therapy of last resort in these cases. We report on a 65-year-old woman suffering from exacerbated COPD, who could not be sufficiently ventilated despite comprehensive pharmacological therapy. In order to administer a volatile anaesthetic in the ICU, we employed the "Anaesthetic Conserving Device" (AnaConDa) consisting of a vaporizer chamber embedded in a charcoal filter system. With this device, every standard intensive care ventilator can be used to deliver volatile anaesthetics in a safe and economic manner. The AnaConDa converts the open breathing system of the intensive care ventilator into a de facto half-closed system. The very low pulmonary compliance of the patient increased dramatically after administration of 0.75 vol% halothane for 48 h (27 vs. 150 ml/mbar). Elimination of CO(2) was improved and weaning from controlled ventilation was achieved. After surgical removal of a pulmonary abscess and a total of 78 days of intensive care therapy, the patient was discharged in good health.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17375268     DOI: 10.1007/s00101-007-1152-6

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  13 in total

1.  Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease.

Authors:  V Snow; S Lascher; C Mottur-Pilson
Journal:  Ann Intern Med       Date:  2001-04-03       Impact factor: 25.391

2.  Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease.

Authors:  James K Stoller
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

Review 3.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

Authors:  A F Connors; N V Dawson; C Thomas; F E Harrell; N Desbiens; W J Fulkerson; P Kussin; P Bellamy; L Goldman; W A Knaus
Journal:  Am J Respir Crit Care Med       Date:  1996-10       Impact factor: 21.405

5.  Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.

Authors:  L Brochard; J Mancebo; M Wysocki; F Lofaso; G Conti; A Rauss; G Simonneau; S Benito; A Gasparetto; F Lemaire
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

6.  Prolonged isoflurane sedation of intensive care unit patients with the Anesthetic Conserving Device.

Authors:  Peter V Sackey; Claes-Roland Martling; Fredrik Granath; Peter J Radell
Journal:  Crit Care Med       Date:  2004-11       Impact factor: 7.598

7.  Effects of ketamine and halothane on normal and asthmatic smooth muscle of the airway in guinea pigs.

Authors:  A Cabanas; J F Souhrada; J A Aldrete
Journal:  Can Anaesth Soc J       Date:  1980-01

Review 8.  [The treatment of status asthmaticus using ketamine--experimental results and clinical experience].

Authors:  A D Krüger; G Benad
Journal:  Anaesthesiol Reanim       Date:  1992

9.  The anesthetic conserving device compared with conventional circle system used under different flow conditions for inhaled anesthesia.

Authors:  Augusto Tempia; Maddalena C Olivei; Eliana Calza; Hans Lambert; Luca Scotti; Eugenio Orlando; Sergio Livigni; Enrica Guglielmotti
Journal:  Anesth Analg       Date:  2003-04       Impact factor: 5.108

10.  A comparison of sevoflurane with halothane, enflurane, and isoflurane on bronchoconstriction caused by histamine.

Authors:  T Katoh; K Ikeda
Journal:  Can J Anaesth       Date:  1994-12       Impact factor: 5.063

View more
  7 in total

1.  [Functioning of the anaesthetic conserving device: aspects to consider for use in inhalational sedation].

Authors:  A Meiser; M Bellgardt; H Vogelsang; C Sirtl; T Weber
Journal:  Anaesthesist       Date:  2010-11       Impact factor: 1.041

2.  [Sedation concepts with volatile anaesthetics in intensive care: practical use and current experiences with the AnaConDa system].

Authors:  J Kompardt; K Schärff; K Kubosch; C Pohl; M Bomplitz; J Soukup
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

3.  [Status asthmaticus. Role of extracorporeal lung assist procedures].

Authors:  L Aniset; A Kalenka
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 4.  [New technical developments for inhaled sedation].

Authors:  A Meiser; H Bomberg; T Volk; H V Groesdonk
Journal:  Anaesthesist       Date:  2017-04       Impact factor: 1.041

5.  Technical performance and reflection capacity of the anaesthetic conserving device--a bench study with isoflurane and sevoflurane.

Authors:  Andreas Meiser; Martin Bellgardt; Javier Belda; Kerstin Röhm; Heinz Laubenthal; Clemens Sirtl
Journal:  J Clin Monit Comput       Date:  2009-02-03       Impact factor: 2.502

Review 6.  [Anesthesia in a patient after endoscopic lung volume reduction. First anesthesiological experiences with implanted endobronchial valves].

Authors:  P Hilbert; K-P Litwinenko; B Niemann; K zur Nieden
Journal:  Anaesthesist       Date:  2014-09       Impact factor: 1.041

Review 7.  [Bronchial asthma and chronic obstructive pulmonary disease with acute exacerbation: preclinical differential diagnostic and emergency treatment].

Authors:  B Friege; L Friege; J Pelz; M Weber; T von Spiegel; S Schröder
Journal:  Anaesthesist       Date:  2009-06       Impact factor: 1.041

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.